97 related articles for article (PubMed ID: 12383370)
1. p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study.
Kurtkaya-Yapicier O; Scheithauer BW; Hebrink D; James CD
Neurosurgery; 2002 Nov; 51(5):1246-54; discussion 1254-5. PubMed ID: 12383370
[TBL] [Abstract][Full Text] [Related]
2. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions.
Yaziji H; Massarani-Wafai R; Gujrati M; Kuhns JG; Martin AW; Parker JC
Am J Surg Pathol; 1996 Sep; 20(9):1086-90. PubMed ID: 8764745
[TBL] [Abstract][Full Text] [Related]
3. Expression of Bax, Bcl-2, and P53 in progressive multifocal leukoencephalopathy.
Yang B; Prayson RA
Mod Pathol; 2000 Oct; 13(10):1115-20. PubMed ID: 11048806
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
5. J1-31 protein expression in astrocytes and astrocytomas.
Shuangshoti S; Thorner PS; Ruangvejvorachai P; Saha B; Groshen S; Taylor CR; Malhotra S; Imam SA
Neuropathology; 2009 Oct; 29(5):521-7. PubMed ID: 19019178
[TBL] [Abstract][Full Text] [Related]
6. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of wild type p53 protein in human astrocytomas.
Rubio MP; von Deimling A; Yandell DW; Wiestler OD; Gusella JF; Louis DN
Cancer Res; 1993 Aug; 53(15):3465-7. PubMed ID: 8339248
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
10. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
11. Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas.
Takami H; Yoshida A; Fukushima S; Arita H; Matsushita Y; Nakamura T; Ohno M; Miyakita Y; Shibui S; Narita Y; Ichimura K
Brain Pathol; 2015 May; 25(3):256-65. PubMed ID: 25040820
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
13. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.
Burel-Vandenbos F; Benchetrit M; Miquel C; Fontaine D; Auvergne R; Lebrun-Frenay C; Cardot-Leccia N; Michiels JF; Paquis-Flucklinger V; Virolle T
J Neurooncol; 2011 Apr; 102(2):171-8. PubMed ID: 20652725
[TBL] [Abstract][Full Text] [Related]
14. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
15. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
16. Reactive astrocytes in viral infections of the human brain express endothelin-like immunoreactivity.
Ma KC; Nie XJ; Höög A; Olsson Y; Zhang WW
J Neurol Sci; 1994 Nov; 126(2):184-92. PubMed ID: 7531760
[TBL] [Abstract][Full Text] [Related]
17. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
19. p53 protein overexpression in astrocytic neoplasms.
Cho MY; Jung SH; Kim TS
Yonsei Med J; 1995 Dec; 36(6):521-6. PubMed ID: 8599254
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical study of p53 and proliferating cell nuclear antigen expression in progressive multifocal leukoencephalopathy.
Lammie GA; Beckett A; Courtney R; Scaravilli F
Acta Neuropathol; 1994; 88(5):465-71. PubMed ID: 7847076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
